Beatriz Sanchez-Alamo

Beatriz Sanchez-Alamo

Auto-generated profile, based on publicly available information

Beatriz Sanchez-Alamo

Hospital Universitario Ramón y Cajal, IRYCIS Department of Nephrology Madrid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Nephron
Verified
Journal Article
Closed access
PDF file
BSBeatriz Sanchez-Alamo
Beatriz Sanchez-Alamo
CCClara Cases-Corona
Clara Cases-Corona
GJGema Maria Fernández Juárez
Gema Maria Fernández Juárez
Background: Acute interstitial nephritis (AIN) is one of the chief causes of acute kidney injury (AKI). AIN might be produced by drugs, infections, autoimmune diseases, or can be idiopathic. Among these etiologies, drug-induced AIN (DI-AIN) is the dominant one in many countries. Even when DI-AIN is suspected, identification of the putative drug is challenging. Summary: DI-AIN is an increasingly common cause of AKI. Diagnosis continues to pose a challenge for physicians due to nonspecific clinical symptoms, and the fact that it can be triggered by a wide variety of medications. Furthermore, the gold standard for the diagnosis is kidney biopsy. All these aspects render the diagnosis more difficult. The withdrawal of the causative drug of DI-AIN is the centerpiece of the treatment, and if early restoration of original kidney function is not obtained, several studies support the treatment with steroids especially when they are started quickly. Key Messages: Almost all drugs have the potential to produce drug-induced acute interstitial nephritis (DI-AIN); however, antibiotics, nonsteroidal anti-inflammatory agents, and proton pump inhibitors account for the majority of the reported cases. DI-AIN is produced by an idiosyncratic delayed type IV hypersensitivity reaction, but the precise pathophysiological mechanism remains to be elucidated. DI-AIN symptoms are nonspecific, and most of the patients will present mild symptoms including malaise, nausea, and vomiting. The classical triad, associating fever, rash, and eosinophilia, is seldom present. Nonoliguric acute kidney injury is the main renal manifestation of DI-AIN. Tubular nonnephrotic range proteinuria is usually present. Diagnosis of DI-AIN relies on maintaining a high index of suspicion in those patients at greater risk, but kidney biopsy is required to confirm diagnosis. Histologically, AIN is characterized by the presence of an extensive interstitial infiltrate, mainly composed of lymphocytes and monocytes, but eosinophils, plasma cells, histiocytes, and polymorphonuclear cells can also be found. The withdrawal of the presumed causative drug of DI-AIN is the mainstay of the treatment. When there is no evidence of kidney function recovery after an interval of 5–7 days since interrupting the treatment with the suspected drug, several studies support the treatment with steroids, especially when they are promptly started. Early corticosteroids would decrease the inflammatory infiltrates of the kidney interstitium, thus preventing the risk of subsequent fibrosis.

21 July 2023 in RMD Open
Verified
Journal Article
Open access
PDF file
JSJan Henrik Schirmer
Jan Henrik Schirmer
BSBeatriz Sanchez-Alamo
Beatriz Sanchez-Alamo
BHBernhard Hellmich
Bernhard Hellmich
DJDavid Jayne
David Jayne
SMSara Monti
Sara Monti
GTGunnar Tomasson
Gunnar Tomasson
Objective To summarise and update evidence to inform the 2022 update of the EULAR recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis (AAV). Methods A systematic literature review (SLR) was performed to identify current evidence regarding treatment of AAV. PubMed, EMBASE and the Cochrane library were searched from 1 February 2015 to 25 February 2022. The evidence presented here is focused on the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. Results 3517 articles were screened and 175 assessed by full-text review. Ninety articles were included in the final evidence synthesis. Cyclophosphamide and rituximab (RTX) show similar efficacy for remission induction (level of evidence (LoE) 1a) but RTX is more effective in relapsing disease (LoE 1b). Glucocorticoid (GC) protocols with faster tapering result in similar remission rates but lower rates of serious infections (LoE 1b). Avacopan can be used to rapidly taper and replace GC (LoE 1b). Data on plasma exchange are inconsistent depending on the analysed trial populations but meta-analyses based on randomised controlled trials demonstrate a reduction of the risk of end-stage kidney disease at 1 year but not during long-term follow-up (LoE 1a). Use of RTX for maintenance of remission is associated with lower relapse rates compared with azathioprine (AZA, LoE 1b). Prolonged maintenance treatment results in lower relapse rates for both, AZA (LoE 1b) and RTX (LoE 1b). Conclusion This SLR provides current evidence to inform the 2022 update of the EULAR recommendations for the management of AAV.

22 June 2023 in RMD Open
Verified
Journal Article
Open access
PDF file
BSBeatriz Sanchez-Alamo
Beatriz Sanchez-Alamo
JSJan Henrik Schirmer
Jan Henrik Schirmer
BHBernhard Hellmich
Bernhard Hellmich
DJDavid Jayne
David Jayne
SMSara Monti
Sara Monti
RLRaashid Ahmed Luqmani
Raashid Ahmed Luqmani
Objective To summarise and update evidence to inform the 2022 update of the European Alliance of Associations of Rheumatology (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods Three systematic literature reviews (SLR) were performed. PubMed, EMBASE and the Cochrane library were searched from 1 February 2015 to 25 February 2022. The evidence presented herein covers the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) as well as diagnostic testing and general management of all AAV syndromes. Results For the treatment of EGPA, diagnostic procedures and general management 3517, 4137 and 4215 articles were screened and 26, 110 and 63 articles were included in the final evidence syntheses, respectively. For EGPA patients with newly diagnosed disease without unfavourable prognostic factors, azathioprine (AZA) combined with glucocorticoids (GC) is not superior to GC monotherapy to induce remission (LoE 2b). In patients with active EGPA and unfavourable prognostic factors, cyclophosphamide or rituximab can be used for remission induction (LoE 2b). Treatment with Mepolizumab added to standard treatment results in higher rates of sustained remission in patients with relapsing or refractory EGPA without active organ-threatening or life-threatening manifestations (LoE 1b) and reduces GC use. Kidney biopsies have prognostic value in AAV patients with renal involvement (LoE 2a). In the context of suspected AAV, immunoassays for proteinase 3 and myeloperoxidase-ANCA have higher diagnostic accuracy compared with indirect immunofluorescent testing (LoE 1a). Conclusion This SLR provides current evidence to inform the 2022 update of the EULAR recommendations for the management of AAV.

13 March 2026 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
BABeatriz Sánchez Alamo
Beatriz Sánchez Alamo
IMIrene Minguez
Irene Minguez
MDMartha Elisabeth Díaz Domínguez
Martha Elisabeth Díaz Domínguez
NMNuria Rodríguez Mendiola
Nuria Rodríguez Mendiola
MLMilagros Fernández Lucas
Milagros Fernández Lucas
Residual kidney function (RKF) is a major prognostic determinant in hemodialysis (HD), strongly influencing morbidity, mortality, and quality of life. Although proteinuria is a well-established marker of chronic kidney disease (CKD) progression, its prognostic relevance at the initiation of HD remains uncertain. This study aimed to assess the association between baseline proteinuria and RKF decline during the first year of HD. We performed a prospective study of incident online-HDF patients with preserved RKF, defined as kidney urea clearance (KrU) ≥ 2.5 mL/min and urine output >500 mL/day. The primary endpoint was RKF loss at one year, defined as KrU < 2.5 mL/min. Secondary endpoints included changes in creatinine clearance (KrCr), glomerular filtration rate (GFR), and 24-hour urine volume. Proteinuria was quantified using both 24-hour urinary protein excretion and the urine protein-to-creatinine ratio. Ninety-seven patients were included; 74.2% were male, with a mean age of 64.3 ± 15 years. Among the 35 patients who reached the primary outcome, 62.9% had nephrotic-range proteinuria, compared with 25.5% with proteinuria < 3.5 g/24 h (P = 0.02). Of those whose urine output fell below 500 mL/day at one year, 73% had baseline proteinuria ≥ 3.5 g/24 h. The most frequent underlying nephropathies among patients with RKF loss were diabetic kidney disease (43%), vascular disease (17%), and glomerulonephritis (17%). Patients with proteinuria ≥ 3.5 g/24 h reached RKF loss significantly earlier (log-rank = 5.25; P = 0.02). Nephrotic-range proteinuria was associated with a higher risk of RKF decline (HR = 2.04;95%CI 1.03–4.02; P = 0.04), a finding that remained consistent across adjusted models. β2-microglobulin levels were also significantly higher in this group. Nephrotic-range proteinuria at online-HDF initiation is an independent predictor of accelerated RKF loss, including progression to anuria. Its association with elevated β2-microglobulin supports its value as a prognostic marker. Early identification of high-proteinuria patients may enable personalized strategies to preserve RKF and improve outcomes.

23 March 2022
Verified
Book Chapter
Closed access
PDF file
BSBeatriz Sanchez-Alamo
Beatriz Sanchez-Alamo
CCClara Cases-Corona
Clara Cases-Corona
GJGema Maria Fernández Juárez
Gema Maria Fernández Juárez